MX2009008022A - Metodos y composiciones para tratar neuropatias. - Google Patents

Metodos y composiciones para tratar neuropatias.

Info

Publication number
MX2009008022A
MX2009008022A MX2009008022A MX2009008022A MX2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A
Authority
MX
Mexico
Prior art keywords
methods
activity
treating
neuropathies
compositions
Prior art date
Application number
MX2009008022A
Other languages
English (en)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2009008022A publication Critical patent/MX2009008022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para tratar o prevenir la degradación axonal en enfermedades neuropáticas y trastornos neurológicos en mamíferos; los métodos pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa, por lo menos en parte, aumentando la actividad sirtuinAMPK, la actividad LKB 1 y/o la actividad CaMKKß en neuronas enfermas y/o lesionadas; los métodos también pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa aumentando la cavidad de NAD en neuronas enfermas y/o lesionadas, solo o en combinación con agentes que actúan por otros mecanismos; también se describen métodos para analizar agentes para el tratamiento de neuropatías y vectores recombinantes para el tratamiento o la prevención de dichas neuropatías.
MX2009008022A 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias. MX2009008022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88685407P 2007-01-26 2007-01-26
PCT/US2008/001085 WO2008091710A2 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
MX2009008022A true MX2009008022A (es) 2009-12-11

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008022A MX2009008022A (es) 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias.

Country Status (5)

Country Link
US (3) US20100047177A1 (es)
EP (1) EP2124985A4 (es)
CA (1) CA2676609A1 (es)
MX (1) MX2009008022A (es)
WO (1) WO2008091710A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221634B2 (en) 2008-03-03 2014-05-08 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
WO2010011836A2 (en) * 2008-07-25 2010-01-28 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
BRPI0917626A2 (pt) 2008-12-08 2017-07-11 Univ Northwestern Método para modular atividade do fator 1 de transcrição do choque térmico (hsf1) em uma célula, método para aumentar ou diminuir a atividade de hsf1 em um indivíduo necessitando do mesmo método para tratar um paciente, método para identificar um agente que modula a atividade de hsf1 em uma célula, método para ativar a resposta ao choque térmico em uma célula ou em um paciente necessitando do mesmo e composição farmacêutica
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Ｌｋｂ１活性化剤
WO2011156479A2 (en) 2010-06-09 2011-12-15 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
US9593125B2 (en) 2012-07-27 2017-03-14 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP2968306B1 (en) 2013-03-15 2023-06-07 Washington University Administration of nicotinamide mononucleotide in the treatment of dry eye
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
ES2908332T3 (es) 2014-07-24 2022-04-28 Grace W R & Co Forma cristalina de cloruro de ribosilnicotinamida
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
US20170068860A1 (en) * 2015-09-09 2017-03-09 Alex Adekola System for measuring crowd density
US20190203207A1 (en) * 2016-05-20 2019-07-04 The Trustees Of Columbia University In The City Of New York Anabolic Enhancers for Ameliorating Neurodegeneration
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
AU2020215510A1 (en) 2019-01-28 2021-07-22 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
EP3917508A4 (en) 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
IT202000007726A1 (it) * 2020-04-10 2021-10-10 Solongevity Nutraceuticals S R L Composizioni mimetiche della restrizione calorica
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
AU2022226257A1 (en) * 2021-02-26 2023-09-07 Icahn School Of Medicine At Mount Sinai Method for decreasing degeneration of retinal ganglion cells
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106354A1 (en) * 1998-04-28 2002-08-08 Christen M. Anderson Cellular and animal models for diseases associated with altered mitochondrial function
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US6514719B1 (en) * 1999-05-28 2003-02-04 Immunex Corporation Methods for identifying compounds that alter kinase activity
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP2236131A3 (en) * 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005004814A2 (en) * 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
EP1723227A4 (en) * 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
US20070244202A1 (en) * 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CN103055313A (zh) * 2005-07-07 2013-04-24 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
WO2007019344A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds
CA2675638C (en) * 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome

Also Published As

Publication number Publication date
EP2124985A4 (en) 2011-06-08
EP2124985A2 (en) 2009-12-02
US20100047177A1 (en) 2010-02-25
US20160367497A1 (en) 2016-12-22
CA2676609A1 (en) 2008-07-31
WO2008091710A3 (en) 2008-10-09
US20140011890A1 (en) 2014-01-09
WO2008091710A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
WO2006001982A3 (en) Methods and compositions for treating neuropathies
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
HRP20130707T1 (en) Compositions and uses for treating multiple sclerosis
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2005000331A3 (en) Compositions for the treatment and prevention of degenerative joint disorders
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2006128032A3 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
WO2007040565A3 (en) Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
EP3150635A3 (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007022470A3 (en) Methods and compositions for treating neurological disease
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2006055970A3 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006085143A3 (en) Improved bioactive agent compositions for repair of cell injuries
WO2006078574A3 (en) Mitotic kinesin inhibitors
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal